The liver x receptors (LXRs) are key regulators of systemic lipid metabolism. We identified 25 transmembrane protein 135 (TMEM135), a peroxisomal protein with an unknown function, as a 26 novel LXR target gene. The LXRs directly induce TMEM135 transcription in humans via an LXR 27 response element in the 5' untranslated region, but do not increase Tmem135 in murine cells. 28
Summary 24
The liver x receptors (LXRs) are key regulators of systemic lipid metabolism. We identified 25 transmembrane protein 135 (TMEM135), a peroxisomal protein with an unknown function, as a 26 novel LXR target gene. The LXRs directly induce TMEM135 transcription in humans via an LXR 27 response element in the 5' untranslated region, but do not increase Tmem135 in murine cells. 28
Functionally, knockdown of TMEM135 in vitro and in vivo results in many features typical of 29 peroxisomal disorders such as steatosis and reduced peroxisomal β-oxidation. Mechanistically, 30 proteomic and Western blot analyses indicated that TMEM135 mediates import of peroxisome 31 matrix proteins necessary for β-oxidation and bile acid synthesis. These findings indicate that 32
Introduction 36
The liver x receptors (LXR) α (NR1H3) and β (NR1H2) belong to the nuclear receptor 37 superfamily and are key regulators of cholesterol and fatty acid metabolism (1) . Natural LXR 38 ligands include oxysterols (2) that increase during cholesterol loading and activate LXR-mediated 39 transcription. The LXRs heterodimerize with the retinoic acid receptor (RXR) and bind to LXR 40 response elements (LXRE) within the promoters of target genes (2). The LXREs belong to the 41 direct repeat 4 (DR4) class that consist of two hexanucleotide half-sites separated by a 4-42 nucleotide spacer (3,4). The protein products of known LXR target genes affect systemic lipid 43
metabolism. Well known examples include increasing cholesterol efflux via ATP-binding cassette 44
(ABC) sub-family A, member 1 (ABCA1) (5), and sub-family G, member 1 (ABCG1) (6); limiting 45 cholesterol uptake via induction of myosin regulatory light chain interacting protein (MYLIP) that 46 targets the low-density lipoprotein receptor (LDLR) for ubiquitin-mediated degradation (7); and 47 increased lipogenesis via induction of sterol regulatory element binding protein 1c (SREBP1c, 48 encoded by sterol regulatory element binding transcription factor 1 gene or SREBF1) (8,9). Also, 49 3 nucleotides within both hexanucleotide half-sites were unique in mice ( Figure S2A ). In mouse 128 hepatocyte (BNL 1NG A.2) and macrophage (RAW 264.7) cell lines, T09 did not significantly 129 induce Tmem135 mRNA expression ( Figure S2B ) whereas it did increase the known LXR target 130 gene Abca1 ( Figure S2C ). These data indicate that Tmem135 is not an LXR target gene in mice. 131
TMEM135 is a Direct Target Gene of the LXRs 132
To directly determine whether the LXRs are needed for T09-induced TMEM135 133 transcription, siRNA-mediated knockdown of the LXRs was performed in HepG2 cells. The 134 NR1H2 siRNA caused an approximately 75% decrease (p< 0.05) in NR1H2 mRNA expression 135 compared to the control and NR1H3 siRNA groups ( Figure 3A ). The NR1H3 siRNA resulted in an 136 approximately 70-80% decrease (p< 0.05) in NR1H3 mRNA expression compared to the control 137 siRNA depending on the presence or absence of T09 ( Figure 3B ). The NR1H2 siRNA by itself 138 also caused a significant reduction in T09-stimulated NR1H3 mRNA expression and tended to 139 slightly improve NR1H3 knockdown when co-transfected with the NR1H3 siRNA ( Figure 3B ). 140
Decreased NR1H3 mRNA expression is expected to occur following NR1H2 knockdown because 141 NR1H3 itself is an LXR target gene (6,11). Consistent with NR1H3 being an LXR target gene, 142 T09 induced a significant increase in NR1H3 in the control siRNA group, while T09 was not as 143 effective at inducing NR1H3 in the NR1H2 siRNA group ( Figure 3B) . 144
The known LXR target gene ABCA1 was significantly increased by T09 in the control 145 siRNA group, and the effect of T09 was completely abolished by NR1H2/NR1H3 siRNA co-146 transfection ( Figure 3C ). Also, NR1H3 knockdown alone significantly inhibited the T09-induced 147 increase in ABCA1 ( Figure 3C ). Results for TMEM135 were very similar to ABCA1 with T09 148 causing a significant increase in the control siRNA group, and the effect of T09 was completely 149 blocked by NR1H2/NR1H3 siRNA co-transfection ( Figure 3D ). Furthermore, NR1H3 knockdown 150 itself significantly inhibited the T09-induced increase in TMEM135 as compared to the control 151 siRNA ( Figure 3D ). 152
The LXRE3 site of the human TMEM135 promoter lies downstream of the putative 153 transcriptional start site, but before the translation initiation site ( Figure S1 ). To determine whether 154 LXR-mediated transcription of TMEM135 results in an mRNA with a truncated 5' UTR, primers 155 and a probe were designed to amplify and detect a 76 base pair region encompassing the LXRE3 156 site in the 5' UTR. There was a significant (p< 0.05) reduction in mRNA expression of full-length 157 5' UTR transcripts caused by T09 in the control siRNA group, while this effect was blocked by 158 NR1H2/NR1H3 siRNA co-transfection ( Figure 3E ). Furthermore, NR1H2/NR1H3 co-knockdown 159 resulted in a significant (p< 0.05) increase in basal mRNA expression of full-length 5' UTR 160 transcripts compared to all other groups ( Figure 3E ). ChIP was used to determine if the reduction 161 in full-length 5' UTR transcripts is associated with increased NR1H2 and/or NR1H3 binding to the 162 LXRE3 site on the TMEM135 gene. Monoclonal antibodies specific for each LXR isoform were 163 used for ChIP, and QPCR of the LXRE3 region on chromatin purified via ChIP indicated that T09 164 treatment caused a significant increase in binding of NR1H3 to LXRE3 in the TMEM135 gene 165 ( Figure 3F ). This indicates that LXR binding to LXRE3 increases mRNA expression of TMEM135 166 via a transcript with a truncated 5' UTR relative to the putative mRNA sequence. 167
TMEM135 Mediates Fatty Acid Metabolism and Proliferation in HepG2 Cells 168
To begin unraveling the biologic function of TMEM135, a series of knockdown experiments 169 were performed. Transfection of HepG2 cells with siRNA against TMEM135 decreased its mRNA 170 expression by 70-90%. As TMEM135 has previously been implicated in fat metabolism (15), and 171 the LXRs are known to induce lipogenesis (1), we first determined its effect on triglycerides and 172 mRNA expression of fatty acid oxidation and lipogenesis-associated genes. Knockdown of 173 TMEM135 significantly increased basal triglyceride accumulation in HepG2 cells ( Figure 4A ). 174
Furthermore, T09 significantly increased intracellular triglyceride concentrations, while TMEM135 175 knockdown further increased triglyceride accumulation in the presence of T09 ( Figure 4A ). An 176 increase in triglyceride accumulation could result from a decrease in fatty acid oxidation and/or 177 an increase in lipogenesis. There were no significant effects of TMEM135 knockdown on mRNA 178 expression of the key regulator of fatty acid β-oxidation, peroxisome proliferator activated receptor 179 alpha (PPARA), while it tended to increase the PPARA target gene carnitine palmitoyltransferase 180 1A (CPT1A) (18) ( Figure 4B ). It is known that the LXRs induce lipogenesis via induction of 181 SREBP1c (SREBF1 gene) (8,9). As expected, T09 caused a significant increase in SREBF1 and 182 the SREBP1c/LXR target gene fatty acid synthase (FASN) (Figure 4B ), consistent with the T09-183 induced increase in triglyceride accumulation ( Figure 4A ). However, TMEM135 knockdown 184 significantly suppressed both basal and T09-induced SREBF1 mRNA expression ( Figure 4B) . 185
This indicates that the increase in triglyceride accumulation in HepG2 cells due to TMEM135 186 knockdown is likely not due to enhanced lipogenesis. Thus, an inhibition of fatty acid oxidation 187 seems a more likely explanation for the increase in triglyceride accumulation. Further supporting 188 the possibility that fatty acid oxidation is impaired, TMEM135 knockdown reduced ATP 189 concentrations when HepG2 cells were incubated in glucose-free medium ( Figure 4C) . To determine the physiologic function of TMEM135, a siRNA knockdown experiment was 209 performed in male C57BL/6 mice. Mice received either a non-targeting control or Tmem135 210 siRNA and were sacrificed 4 days later in either the ad libitum fed state or after a 12 hour fast. 211
Because we determined that Tmem135 is not an LXR target gene in mice ( Figure S2B ), we used 212 fasting to induce hepatic fat accumulation. Tail-vein delivery of the Tmem135 siRNA caused an 213 approximately 60% mRNA knockdown in the liver while no knockdown was observed in other 214 tissues including skeletal muscle, adipose, and heart ( Figure 5A ). Knockdown of TMEM135 in the 215 liver was further confirmed by Western blot and proteomic analysis of mitochondria/peroxisome-216 enriched fractions ( Figure 5B ). Fed mice injected with the Tmem135 siRNA gained significantly 217 less weight during the 4-day siRNA treatment, while the loss in weight due to fasting was similar 218 for both siRNAs ( Figure 5C ). There was no significant effect of the Tmem135 siRNA on basal or 219 fasting-induced hepatic triglycerides ( Figure S3A ), while there was a tendency for increased 220 hepatic non-esterified fatty acid (NEFA) concentrations in TMEM135 knockdown mice in the fed 221 state ( Figure S3B ). There were no significant effects of TMEM135 knockdown on liver ATP or 222 glycogen concentrations ( Figure S3C-D) . Also, there were no significant effects of TMEM135 on 223 serum lipids (total cholesterol, HDL cholesterol, triglycerides), although there was a trend for 224 reduced serum triglycerides in fed mice receiving the control siRNA that was not observed in 225 TMEM135 knockdown mice ( Figure S4A ). There were no significant effects of TMEM135 226 knockdown on serum NEFA, glucose, or insulin concentrations ( Figure S4B-D) . The mRNA 227 expression of key genes involved in fatty acid β-oxidation were determined in the liver. As 228 expected, fasting significantly induced mRNA expression of Ppara, Cpt1a, acyl-CoA 229 dehydrogenase medium chain (Acadm), uncoupling protein 2 (Ucp2), and sirtuin 3 (Sirt3) (Figure  230 5D). Similarly, knockdown of TMEM135 significantly increased Acadm and Sirt3 in fed animals, 231
while Ucp2 increased with fasting in control but not TMEM135 knockdown animals ( Figure 5D ). 232
As expected with increased β-oxidative flux, fasting significantly increased NADH in animals 233 receiving the control siRNA, which was prevented by TMEM135 knockdown ( Figure 5E ) indicating 234 an impairment in β-oxidation in these mice. Reduced hepatic NADH during fasting could be due 235 to reduced β-oxidation in peroxisomes and/or mitochondria. However, there was a reciprocal 236 increase in hepatic ketone concentrations in fasted mice with TMEM135 knockdown ( Figure 5F ). 237
Because ketogenesis occurs exclusively in mitochondria and is dependent on fatty acid oxidation 238 (22), this indicates that mitochondrial fatty acid β-oxidation was not impaired. Thus, knockdown 239 mice have impaired fatty acid β-oxidation in peroxisomes but not mitochondria. 240
TMEM135 Mediates Import of Peroxisome Matrix Proteins Involved in Fatty Acid β-Oxidation and 241

Bile Acid Synthesis 242
TMEM135 is a peroxisomal protein with high homology to the Tim17 family that mediate 243 translocation of proteins across mitochondrial membranes (23). In addition to peroxisomes, 244 TMEM135 has been reported to be localized to mitochondria (15,16). Therefore, we hypothesized 245 that TMEM135 mediates protein import into peroxisomes and/or mitochondria. A 246 mitochondria/peroxisome-enriched fraction was prepared from frozen mouse livers. This fraction 247 was validated to contain both mitochondria and peroxisomes as indicated by presence of the 248 mitochondria marker cytochrome c oxidase subunit 4I1 (COX4I1) and the peroxisome marker 249 ATP binding cassette subfamily D member 3 (ABCD3, also known as PMP70), while COX4I1 and 250 ABCD3 were undetectable in the cytosolic supernatant ( Figure 6A ). Furthermore, the cytosolic 251 protein tubulin beta class I (TUBB) segregated to the cytosolic fraction and was not detected in 252 the mitochondria/peroxisome-enriched fraction. Proteomic analysis of a subset of fed mice was 253 used to provide an unbiased estimate of differential protein abundance in the 254 mitochondria/peroxisome-enriched fractions. A total of 23 proteins were significantly less 255 abundant (Fisher's Exact Test, p< 0.05) in the mitochondria/peroxisome-enriched fraction from 256 TMEM135 knockdown livers ( Figure 6B ). Of particular interest was the finding that these 23 257 proteins included nearly all of the matrix proteins known to be necessary for bile acid synthesis 258 and peroxisomal β-oxidation of very-long chain fatty acids, branched chain fatty acids, and 259 dicarboxylic acids (24,25) ( Figure 6 C-D) . Four proteins were selected for further analysis via 260
Western blot: acetyl-CoA acyltransferase 1 (ACAA1), acyl-CoA oxidase 1 (ACOX1), sterol carrier 261 protein 2 (SCP2), and catalase (CAT). All these proteins were enriched in the 262 mitochondria/peroxisome fraction, but except for SCP2 (which may be due to low detection 263 sensitivity) each protein was also clearly detectable in the cytosolic fraction ( Figure 6E ). This 264 contrasts with the peroxisome membrane protein ABCD3 which appeared to be exclusively 265 localized to the mitochondria/peroxisome fraction ( Figure 6A ). Collectively, detection of these 266
proteins in the cytoplasm indicates that their import into peroxisomes may be rate-limiting. 267
We next used Western blot to quantitatively determine import of ACAA1, ACOX1, SCP2, 268
and CAT into peroxisomes. Whole cell lysates (using TUBB as loading control) and 269 mitochondria/peroxisome-enriched fractions (using COX4I1 and ABCD3 as loading controls for 270 mitochondria and peroxisome content, respectively) were analyzed ( Figure 7A ). The signal for 271 each protein was normalized to the respective loading control, and the ratio of peroxisome to 272 whole cell lysate was used to determine import. There were no significant differences in 273 peroxisome content of the mitochondria/peroxisome-enriched fraction with TMEM135 knockdown 274 as indicated by the ABCD3:COX4I1 ratio, indicating that differences detected by proteomic 275 analysis are not simply due to effects on peroxisome proliferation ( Figure 7B ). When using ABCD3 276 to correct for variations in peroxisome content of the mitochondria/peroxisome-enriched fraction, 277 there were no significant differences between siRNAs for peroxisome import of ACOX1 and CAT 278 in either fed or fasted animals ( Figure 7C ). However, relative ACAA1 import was significantly 279 reduced in TMEM135 knockdown mice when fasted ( Figure 7C ). Furthermore, SCP2 import was 280 significantly lower in TMEM135 knockdown mice in both the fed and fasted state ( Figure 7C ). 281
Thus, TMEM135 mediates the import of ACAA1 and SCP2 into peroxisomes. 282
Discussion 283
Peroxisomes have key catabolic functions including α and β-oxidation of fatty acids, and 284 anabolic activities including the synthesis of bile acids and ether phospholipids (24,25). There are 285 2 main classes of peroxisome disorders: 1) peroxisome biogenesis disorders, and 2) single 286 peroxisomal enzyme deficiencies (24,25). Outcomes from these disorders range from infant death 287 to mild degenerative neurosensory problems (24,25). Hepatic pathologies are one of the principal 288 features associated with peroxisome disorders, which are often caused by a failure to import 289 matrix enzymes into peroxisomes (24). In the current study we determined that TMEM135, a 290 protein predicted to be associated with peroxisomes based on homology but with a previously 291 unknown function, is an LXR-inducible protein that mediates the import of proteins into 292
peroxisomes. 293
Many effects of hepatocyte-specific TMEM135 knockdown in the current study are 294 consistent with typical features of peroxisomal disorders. Knockdown of TMEM135 causes an 295 accumulation of fatty acids both in vitro and in vivo. In HepG2 cells, TMEM135 knockdown 296 increased triglyceride concentrations despite a simultaneous significant reduction in mRNA 297 expression of SREBF1, the key regulator of lipogenesis ( Figure 4A-B) . This resembles liver-298 specific peroxisome deficiency in mice (peroxisomal biogenesis factor 5 or Pex5 conditional 299 knockout), which results in hepatic steatosis despite significantly reduced mRNA expression of 300 Srebf1 (26). In vivo there was a tendency for TMEM135 knockdown to increase hepatic NEFA 301 concentrations in fed mice ( Figure S3B ), which was coupled with a general increase in mRNA 302 expression of PPARA and fasting-induced genes in the fed state such as Acadm (18) and Sirt3 303 (27) ( Figure 5D ). This is consistent with several mouse models of peroxisome deficiency or 304 peroxisomal β-oxidation defects, which are characterized by steatosis and consequently induction 305 of PPARA target genes due to an increase in endogenous PPARA agonists (24). When β-306 oxidation (both peroxisomal and mitochondrial) was stimulated by fasting, TMEM135 knockdown 307 mice had significantly lower NADH concentrations ( Figure 5E ), indicating an impairment in β-308 oxidation. Meanwhile, hepatic ketones were significantly increased in knockdown mice when 309 fasted ( Figure 5F ). Because ketogenesis occurs exclusively in mitochondria, the increase in 310 ketones may have resulted from increased availability of fatty acids to the mitochondria due to a 311 decrease in competition with peroxisomes (28), or due to the increased NAD+/NADH ratio (22). 312
Collectively, this indicates that an impairment in fatty acid β-oxidation occurs at the level of 313 peroxisomes and not mitochondria. One final similarity between TMEM135 knockdown and 314 peroxisomal disorders is that the significant reduction in body weight gain of knockdown mice in 315 the fed state ( Figure 5C ) is consistent with liver-specific peroxisome deficiency in mice that results 316 in a stunting of body growth (26) and severe weight loss when pair-fed with control mice (29). 317
The TMEM135-mediated import of proteins into peroxisomes is a novel pathway. The 318 classical mechanism involves peroxisomal targeting signals (PTS), which are short amino acid 319 sequences at the N or C-terminus that interact with various members of the peroxin family of 320 proteins to facilitate import into the peroxisome matrix (30). Among the proteins whose import was 321 quantified by Western blot in the current study ACOX1 and SCP2 contain a PTS1 sequence on 322 their C-terminus that is recognized by PEX5, and ACAA1 contains a PTS2 sequence at its N-323 terminus that interacts with PEX7 (peroxisomal biogenesis factor 7) (30,31). Therefore, TMEM135 324 is likely not obligatory for their import, but rather serves an auxiliary role. It is not known whether 325 TMEM135-mediated protein import occurs via a mechanism that involves, or occurs 326 independently of, peroxins. Because TMEM135 is a transmembrane protein with TIM17 homology 327 (23), a peroxin-independent mechanism seems most likely. Regardless, TMEM135-mediated 328 protein import may be necessary under conditions of high peroxisome activity when peroxin-329 dependent import becomes saturated. 330
An auxiliary role of TMEM135 in peroxisome protein import makes it a potential therapeutic 331 target. One potential pharmacologic therapy comes from our findings in the current study that 332 TMEM135 is an LXR target gene in humans. The function of TMEM135 fits well with the known 333 roles of the LXRs in cholesterol metabolism. The LXRs are master regulators of reverse 334 cholesterol transport (RCT), a process whereby excess cholesterol is removed from peripheral 335 tissues and transported to the liver for elimination in bile acids (1) . There has been much interest 336 in the development of LXR agonists to treat human diseases including atherosclerosis, 337
Alzheimer's disease, and other metabolic disorders (1) . Because RCT results in cholesterol being 338 converted to bile acids in the liver and the final steps in bile acid synthesis occur in peroxisomes 339 (24), an LXR-induced increase in TMEM135 would help stimulate peroxisomal synthesis of bile 340 acids during periods of cholesterol loading. The LXRs are also known to increase hepatic 341 lipogenesis via their induction of SREBP1c (8,9), which is a master regulator of genes necessary 342 for fatty acid synthesis. In fact, increased hepatic lipogenesis has been the primary obstacle in 343 the development of LXR agonists as therapeutic agents (1) . Elevated TMEM135 expression may 344 increase peroxisomal β-oxidation of fatty acids, and thus limit fat accumulation when lipogenesis 345 is elevated due to LXR activation. It should be noted that our data indicate that TMEM135 is an 346 LXR target gene in humans, but in mice Tmem135 is either not induced by the LXRs or is a low-347 affinity target gene ( Figure S2 ). Thus, LXR agonist-induced hepatic fat accumulation may be less 348 pronounced in humans than in mice due to species differences in LXR regulation of TMEM135 349
transcription. 350
Elevated TMEM135 activity may protect against cholestasis and fatty liver, but may also 351 contribute to hepatic pathologies. For example, metabolomics studies have reported that elevated 352 serum bile acids and urinary bile salts represent the core metabolic phenotype in the transition 353 from healthy liver to fatty liver and HCC (19). Additionally, elevated fatty acid β-oxidation and 354 reduced mitochondrial respiration are part of the metabolic remodeling that occurs in liver disease 355 (19). These metabolic changes that occur during HCC pathogenesis are consistent with excessive 356 peroxisome activity as peroxisomes play a key role in bile acid synthesis, they contribute to fatty 357 acid β-oxidation, and can also indirectly alter mitochondrial respiration (24). In the current study 358 ACADVL deficiency (15). It was discovered that TMEM135 was elevated more than four-fold in 374 the hearts of ACADVL-deficient mice that survived birth (15). Furthermore, cardiac TMEM135 375 expression was increased by both fasting and cold stresses in wild-type mice (15). The ACADVL 376 enzyme catalyzes the first step in mitochondrial fatty acid β-oxidation using fatty acids ranging in 377 length from 14 up to 24 carbons as substrates (35). It is generally believed that mitochondria 378 preferentially oxidize short and medium chain fatty acids (<C12), both mitochondria and 379 peroxisomes oxidize long chain fatty acids (C14-C20), while peroxisomes exclusively oxidize 380 very-long chain fatty acids (>C20) (28). Peroxisomal β-oxidation produces acetyl-CoA and 381 medium chain fatty acids that can be transported to the mitochondria for further oxidation and 382 ATP generation (28,36). Because ACADVL deficiency restricts the mitochondria from directly 383 oxidizing long and very-long chain fatty acids, an upregulation of TMEM135 would promote 384 survival by increasing peroxisomal β-oxidation capacity and the processing of long and very-long 385 chain fatty acids to medium chain fatty acids that are subsequently oxidized in the mitochondria. 386
Furthermore, the first step in peroxisomal β-oxidation generates hydrogen peroxide that is 387 subsequently metabolized by CAT into oxygen and water with the release of heat, which is 388 another mechanism whereby TMEM135 could aid cold stress. The second mechanistic study into 389 TMEM135 function reported that a mutation in Tmem135 was responsible for accelerated aging 390 of the retina in a mouse model of age-related macular degeneration (16). In this study alterations 391 in mitochondrial function associated with TMEM135 were found (16). As will be subsequently 392 discussed, it is not clear whether TMEM135 acts directly within mitochondria, or if its effects on 393 mitochondria are indirect via altered peroxisome function. Nevertheless, it is becoming 394 increasingly apparent that peroxisomal function declines with aging (28), which is consistent with 395 a Tmem135 mutation causing accelerated aging in the retina (16). 396
There is some controversy regarding the subcellular localization of TMEM135. Neither the 397 murine or human TMEM135 proteins contain a PEX19 (peroxisomal biogenesis factor 19) 398 sequence that mediates insertion of some peroxisome membrane proteins (30) as determined by 399 PeroxisomeDB 2.0 (37). There are also no PTS1 or PTS2 motifs in TMEM135 (37). Thus, there 400 is no indication that TMEM135 incorporation into peroxisome membranes involves interaction with 401 peroxins. One potential mechanism of TMEM135 incorporation into peroxisome membranes 402 involves its translation in the endoplasmic reticulum (ER), and incorporation into peroxisomes via 403 an ER-dependent mechanism (30). It has previously been reported that TMEM135 specifically 404 localizes to peroxisomes but not mitochondria as determined using a GFP fusion protein (38), 405 while other studies have reported it to be localized to mitochondria (15,16). However, in studies 406 reporting TMEM135 localization to mitochondria, non-mitochondrial localization was also 407 observed in "dot-like" (15) or a "vesicular expression pattern in the cytoplasm" (16), which could 408 be descriptions of peroxisomes. In Lee et. al. (16), TMEM135 was found in punctate structures 409 on the surface of mitochondria. It is possible that these punctate structures are peroxisomes 410 associated with mitochondria. Indeed, it has become clear that peroxisomes and mitochondria 411 can physically associate with each other via the formation of tethering complexes, which may help 412 in functions such as metabolite transfer between organelles (39). Also, peroxisomes and 413 mitochondria share proteins involved in their division (39), and peroxisome-specific induction of 414 reactive oxygen species production causes increased mitochondrial fragmentation (40). There is 415 some evidence that TMEM135 may regulate mitochondrial division as a Tmem135 mutation was 416 associated with over-fused mitochondrial networks whereas TMEM135 overexpression caused 417 an increase in mitochondrial fission (16). Overall, it seems plausible that TMEM135 is not 418 localized in mitochondria but rather in peroxisomes that can associate with mitochondria, and its 419 effects on mitochondria may be indirectly mediated via altered peroxisome activity. 420
The critical role of peroxisomes in human health is illustrated by the spectrum of 421 peroxisome disorders; but in addition to these inborn errors of metabolism it is becoming 422 increasingly apparent that peroxisomes play key roles in other metabolic and age-related 423 diseases including cancer, neurodegenerative disorders, and diabetes (28). This may be due to 424 direct catabolic and anabolic actions of peroxisomes, as well as interactions between 425 peroxisomes and the ER or mitochondria (28,39). Our data indicate that TMEM135 regulates 426 peroxisome activity by mediating an auxiliary, and inducible, matrix protein import pathway. 427
Furthermore, TMEM135 is an LXR target gene in humans, and is likely to be regulated by other 428 metabolic signaling pathways. These findings implicate TMEM135 as a potential therapeutic 429 target in the treatment of diseases associated with peroxisomal dysfunction. 430
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Further information and requests for resources and reagents should be directed to and Aldrich, Inc.) supplemented with Pen/Strep (100 units/ml penicillin and 100 µg/ml streptomycin) 718 and 10% fetal bovine serum (FBS). THP-1 cells were incubated in RPMI media (Sigma) 719 supplemented with 2-mercaptoethanol (0.05 mM), Pen/Strep, and 10% FBS. THP-1 cells were 720 differentiated into macrophages by treatment with 12-myristate-13-acetate (PMA, 100 ng/ml) for 721 5 days prior to experimentation. 722
Mice 723
All procedures involving mice were approved by the University of Arizona IACUC. Male 724 C57BL/6 mice, 12 weeks of age, were used. Mice were group housed until initiation of 725 experimental procedures, at which point they were switched to individual caging. 726 
METHOD DETAILS 727
Cell Treatments
HepG2 Mitochondria Isolation 738
Cells were harvested and washed three times in 1 ml cell resuspension buffer (1 mM Tris-739
HCl, pH 7.4, 130 mM NaCl, 5 mM KCl, 7.5 mM MgCl2). Cells were then resuspended in 600 µl 740 homogenization buffer (10 mM Tris-HCl, pH 7.4, 10 mM KCl, 0.15 mM MgCl2, plus protease and 741 phosphatase inhibitor cocktail), incubated on ice for 10 min, and homogenized for 30 strokes in a 742 glass dounce homogenizer with a tight-fitting pestle. The homogenate was mixed with 100 µl of 743 2M sucrose and centrifuged at 1,200 × g for 5 min at 4° C, and the supernatant transferred to a 744 new tube. This low speed centrifugation step was repeated two more times. Mitochondria were 745 pelleted by centrifugation at 7,000 × g for 10 min at 4° C and the supernatant removed. The pellet 746 was washed once with 300 µl of mitochondria wash buffer (10 mM Tris-HCl, pH 7.4, 0.15 mM 747
MgCl2, 250 mM sucrose), and centrifuged at 9,500 × g for 5 min. Mitochondria were solubilized in 748 RIPA buffer containing protease and phosphatase inhibitors, and protein concentration was 749 
Reporter Assays 770
The region from -2662 to -1 bp (relative to translation start site) of the human TMEM135 771 promoter was synthesized by Life Technologies. Additionally, the same region of the human 772 TMEM135 promoter was synthesized except that point mutations were introduced into each of 773 the three LXREs ( Figure S1B ). The normal and mutant TMEM135 promoters were cloned into the 774 pGL4.17 vector (Promega) using SacI and XhoI restriction enzyme sites, which expresses firefly 775 luciferase from a promoter cloned into the vector. A unique PacI site was identified in the region 776 between LXRE1 and LXRE2, and a unique EcoRI site was identified in the region between LXRE2 777 and LXRE3. These restriction sites were used to generate six more TMEM135 promoter/pGL4.17 778 constructs so that all possible combinations of wild type and mutated LXREs were obtained. All 779 constructs were verified using DNA sequence analysis. These reporter vectors were transfected 780 Cell lysates were prepared using mammalian protein extraction reagent (Fisher), and the lysate 789 was fractionated to quantify luciferase and β-galactosidase activity using luminescent detection 790 kits (Fisher). The ratio of luciferase to β-galactosidase activity was calculated, and the fold-change 791 in T09 vs DMSO treated cells was determined for each transfection. were isolated by incubating cell pellets in 500 µl of a hypotonic buffer for 15 min on ice (20 mM 797
Tris-HCL, pH 7.4, 10 mM NaCl, 3 mM MgCL2, with protease and phosphatase inhibitor cocktail 798 from Promega). Triton X-100 detergent was added to a 0.5% v:v final concentration to lyse the 799 cells followed by centrifugation at 1200 × g for 10 min to pellet nuclei. The supernatant was 800 removed, and the nuclei pellet washed once with 500 µl hypotonic buffer. The pellet was 801 resuspended in 500 µl of RIPA buffer with protease and phosphatase inhibitors, and nuclei were 802 sonicated in an ice-water bath using a Branson 250 digital sonifier programmed to cycle at a 10% 803 amplitude with 5 seconds on followed by 20 seconds off, and a 3-minute total sonication time that 804 was determined in preliminary time-course studies to produce chromatin of optimal length 805 (approximately 200-1000 base pairs). The sonicated lysates were centrifuged at 8,000 × g for 1 806
minute and the supernatant recovered. An aliquot of cleared lysate was treated with 25 µg RNAse 807 A and 50 µg proteinase K in a buffer containing 500 mM NaCl and heated at 65°C for 1.5 hours 808 to reverse cross-links. The DNA concentration in this aliquot was determined using a fluorometric 809 assay (Life Technologies) following manufacturer recommendations. The quantity of DNA used 810 in each ChIP was held constant within replicates (8 to 10 µg), and 10% of the input amount was 811 saved. Chromatin was diluted to a 500 µl final volume in binding/wash buffer (50 mM Tris, 150 812 mM NaCl, 1% Triton X-100) containing protease and phosphatase inhibitors, and 3 µg of antibody 813 was added per reaction. Tubes were incubated on an end-over-end rotator at 4°C overnight. 814
Antibodies used for ChIP (Abcam) were mouse monoclonal IgG2a including: 1) anti NR1H3 (clone 815 PPZ0412), 2) anti NR1H2 (clone K8917), and 3) non-specific control IgG2a (clone MOPC-173). 816
The following day 25 µl of Protein G-conjugated Dynabeads (Life Technologies) were added and 817 incubated for 1 hour at 4°C. The beads were recovered using a magnet and washed three times 818 at 4°C for 5 minutes each wash with 1 ml of binding/wash buffer. The beads were then washed 819 once in final wash buffer (50mM Tris, 500 mM NaCl, 1% Triton X-100). Elutions were performed 820 with 130 µl elution buffer (100mM NaHCO3, 500mM NaCl, 1% SDS) containing 25 µg RNAse A 821 and 50 µg proteinase K, and ChIP reactions and input controls were incubated on a thermal mixer 822 at 65°C for 1.5 hours. The supernatant was recovered, and DNA purified using PCR purification 823 columns (Life Technologies) following manufacturer recommendations. Purified DNA was 824
analyzed by QPCR in a duplex reaction with primers and a Taqman probe specific for the region 825 spanning LXRE3 on the TMEM135 gene, and a non-specific locus was simultaneously quantified 826 in the same reaction as a control for non-specific DNA carryover (Table S1 ). Serial dilutions of 827 iodide. List mode data files consisting of 10,000 events were acquired and the percentage of cells 859 in G0/G1, S, and G2/M stages was determined with CellQuest PRO software (BD Biosciences). 860
HepG2 ATP Quantification 861
At 48 hours post-siRNA transfection, HepG2 cells were switched to serum-free, glucose-862 free, sodium pyruvate-free DMEM media and incubated at 37°C for 4 hours. Cellular ATP 863 concentrations were determined using a homogenous luminescent ATP detection kit (Abcam 864 catalog ab113849). Additional HepG2 cells treated in parallel to those used for ATP determination 865 were lysed in RIPA buffer and a BCA protein assay (Fisher) was performed, and ATP content 866 was normalized to protein concentrations. 867
Triglyceride Quantification 868
HepG2 cells or frozen mouse liver were sonicated in PBS containing protease and 869 phosphatase inhibitors (Promega) in an ice-water bath using a Branson 250 digital sonifier 870 programmed to cycle at a 10% amplitude with 5 seconds on followed by 20 seconds off, and a 30 871 second total sonication time. Triglycerides were extracted using an organic solvent procedure 872 optimized for triglycerides (42). Lysates were diluted 1:1 with deionized water, and 400 µl of 873 diluted lysate was combined in a glass tube with 1.8 ml of a 4:1 isopropanol:hexane mixture. 874
Samples were vortexed for 1 minute and incubated at room temperature for 30 min. Next, 500 µl 875 of a 1:1 hexane:diethyl ether solution was added, the samples were vortexed as before, and 876 incubated at room temperature for 1 minute. One ml of deionized water was added, samples were 877 vortexed as before, and incubated at room temperature for 20 minutes to allow phase separation. 878
The organic phase was transferred to a new glass tube and dried under a gentle stream of 879 nitrogen in a water bath at 30°C. Dried extracts were dissolved in 200 µl assay buffer (50 mM 880 potassium phosphate, pH 7.0, 0.01% Triton X-100) by 5 total cycles of vortexing for 1 minute and 881 incubating at room temperature for 3 minutes. Extracts (50 µl/well) were transferred to a clear 96 882 well plate, and 250 µl of triglyceride detection reagent (Pointe Scientific, Inc., catalog T7532) was 883 added. Triglyceride standards (Pointe Scientific) diluted in assay buffer were also run with each 884 assay. Plates were incubated at 37°C for 30 minutes with vigorous shaking, and absorbance at 885 500 nm was determined with a Synergy H1 plate reader. The protein concentration in sonicated 886 lysates was determined using a BCA protein assay, and triglyceride content was normalized to 887 protein concentrations. The siRNA complexes were delivered via a 200 µl tail-vein injection at a final siRNA concentration 893 of 1 mg/kg body weight. Mice were weighed prior to siRNA injection and again before 894 euthanization. Mice were euthanized 4 days after siRNA injection at 4 hours after lights on, with 895 the extract were determined using the same enzymatic assay described for serum. 922
Concentrations of acetoacetate were determined using a modified assay based on methods 923 described previously (45,46). Briefly, samples and standards were divided with one portion 924 subjected to boiling (100° C for 5 minutes) to degrade acetoacetate, with the remaining portion 925 kept on ice. A three-fold volume of freshly prepared diazo reagent (46) was then added to all 926 samples and incubated at room temperature in the dark for 30 minutes. The reaction was stopped 927 by adding a 20% volume of 2N NaOH, and absorbance was measured at 480 nm. The 928 absorbance from the boiled sample was subtracted from the respective non-boiled sample, and 929 acetoacetate concentrations were calculated from the resultant standard curve. 930
Liver Subcellular Fractionation 931
Powdered liver (approximately 50 mg) was homogenized for 40 strokes in a glass dounce 932 homogenizer with a tight-fitting pestle using 600 µl of cold fractionation buffer (10 mM Tris-HCl, 933 pH 7.4, 1 mM EGTA, 200 mM sucrose, protease and phosphatase inhibitor cocktail) on ice. The 934 homogenate was transferred to a new tube, and the dounce homogenizer was washed with an 935 additional 600 µl of fractionation buffer and transferred to the same tube. The homogenate was 936 centrifuged at 600 × g for 10 minutes at 4°C to pellet unbroken cells and nuclei, and the 937 supernatant transferred to a new tube. This low speed spin was repeated once more. 938
Mitochondria and peroxisomes were pelleted by centrifugation at 7,000 × g for 10 minutes, and 939 the supernatant (cytosolic fraction) was transferred to a new tube. The pellet was washed with 940 300 µl fractionation buffer and pelleted as before. The pellet was resuspended in 500 µl of 941 fractionation buffer and a 30 µl aliquot was pelleted and solubilized in RIPA buffer for a BCA 942 protein assay. Following protein assay mitochondria/peroxisome fractions were partitioned into 943 30 µg (protein content) aliquots followed by centrifugation and removal of the supernatant, and 944 the pellets were frozen at -80°C. 945 used in proteomic analysis. Because the proteomic data does not follow a normal distribution due 998 to some proteins not being detected in all samples, significant differences in proteomic data were 999 determined from weighted spectra using the non-parametric Fisher's Exact test (p < 0.05) 1000 contained within the Scaffold version 4.8.1 software. The list of proteins that were significantly 1001 reduced in knockdown livers was further trimmed by hand to exclude proteins that were not 1002 detected in all the samples from mice that received the control siRNA. 
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